EZH2 and neoplasm: However, there are also reports of myelodysplastic syndromes (MDS) exhibiting mutations that inactivate EZH2 (Nikoloski et al., 2010), hence highlighting EZH2’s potential to act as a tumor suppressor under certain cellular conditions.